Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Stefanos Grammatikos

Bioprocess Innovations in the Era of Acceleration and Intensification

UCB Pharma

Christian Eckermann

Future Strategies for Bioprocessing

Boehringer Ingelheim RCV GmbH & CoKG

07:30 - 08:20

Registration and Morning Coffee

More
Showing of Streams
10:30 - 11:30

Morning Coffee and Networking

More
Showing of Streams
13:00 - 13:30

Lunch in the Exhibition Hall

More
13:30 - 14:15

Live Labs

More
Showing of Streams
15:45 - 16:15

Afternoon Coffee & Networking

More
Showing of Streams
17:15 - 17:20
Plenary Changeover

Plenary Changeover

More
Showing of Streams
18:20 - 19:50

End of Conference Day Two and Evening Party

More
07:30 - 08:20 50 mins
Registration and Morning Coffee
08:20 - 08:30 10 mins
Cell Culture and Upstream Process Development
Plenary Chairperson's Opening Remarks
08:20 - 08:30 10 mins
Downstream Processing
Plenary Chairperson's Opening Remarks
08:20 - 08:30 10 mins
Process Development and Characterisation Strategies
Plenary Chairperson's Opening Remarks
08:20 - 08:30 10 mins
Bioprocess Analytics and Control Strategies
Plenary Chairperson's Opening Remarks
08:20 - 08:30 10 mins
Vaccines
Plenary Chairperson's Opening Remarks
08:20 - 08:30 10 mins
Viral Safety
Chairpersons Opening Remarks
  • Thomas R. Kreil - Senior Director, Global Pathogen Safety, Baxalta
08:30 - 09:00 30 mins
Info
Cell Culture and Upstream Process Development
Bioprocess Innovations in the Era of Acceleration and Intensification
  • Stefanos Grammatikos - VP - Head of Biotech Sciences, UCB Pharma

Current trends in clinical development acceleration and bioprocess intensification impose an unprecedented compression of CMC development timelines and new bioprocessing challenges downstream of the cell culture bioreactor. In this talk I will present a series of innovations we have introduced, some incremental and some potentially disruptive, in an effort to avoid further complications while rising to the latest challenges of bio CMC development and bioprocessing.

08:30 - 09:00 30 mins
Info
Downstream Processing
Bioprocess Innovations in the Era of Acceleration and Intensification
  • Stefanos Grammatikos - VP - Head of Biotech Sciences, UCB Pharma

Current trends in clinical development acceleration and bioprocess intensification impose an unprecedented compression of CMC development timelines and new bioprocessing challenges downstream of the cell culture bioreactor. In this talk I will present a series of innovations we have introduced, some incremental and some potentially disruptive, in an effort to avoid further complications while rising to the latest challenges of bio CMC development and bioprocessing.

08:30 - 09:00 30 mins
Info
Process Development and Characterisation Strategies
Bioprocess Innovations in the Era of Acceleration and Intensification
  • Stefanos Grammatikos - VP - Head of Biotech Sciences, UCB Pharma

Current trends in clinical development acceleration and bioprocess intensification impose an unprecedented compression of CMC development timelines and new bioprocessing challenges downstream of the cell culture bioreactor. In this talk I will present a series of innovations we have introduced, some incremental and some potentially disruptive, in an effort to avoid further complications while rising to the latest challenges of bio CMC development and bioprocessing.

08:30 - 09:00 30 mins
Info
Bioprocess Analytics and Control Strategies
Bioprocess Innovations in the Era of Acceleration and Intensification
  • Stefanos Grammatikos - VP - Head of Biotech Sciences, UCB Pharma

Current trends in clinical development acceleration and bioprocess intensification impose an unprecedented compression of CMC development timelines and new bioprocessing challenges downstream of the cell culture bioreactor. In this talk I will present a series of innovations we have introduced, some incremental and some potentially disruptive, in an effort to avoid further complications while rising to the latest challenges of bio CMC development and bioprocessing.

08:30 - 09:00 30 mins
Info
Vaccines
Bioprocess Innovations in the Era of Acceleration and Intensification
  • Stefanos Grammatikos - VP - Head of Biotech Sciences, UCB Pharma

Current trends in clinical development acceleration and bioprocess intensification impose an unprecedented compression of CMC development timelines and new bioprocessing challenges downstream of the cell culture bioreactor. In this talk I will present a series of innovations we have introduced, some incremental and some potentially disruptive, in an effort to avoid further complications while rising to the latest challenges of bio CMC development and bioprocessing.

08:30 - 10:00 90 mins
Info
Viral Safety
Ask the Regulators – Regulatory Breakfast Briefing
  • Albert Stühler - Deputy Head of Virus Safety, Paul-Ehrlich-Institut
  • Arifa Khan - Supervisory Microbiologist, FDA

In this hour-long session, delegates will be given the opportunity to pre-submit questions which will then be posed to the regulators and key leaders in the industry. Topics covered historically include:


  • ATMPs
  • Viral safety of raw materials
  • NGS
  • Viral clearance: Removal/Inactivation chromatography, filtration, viral reduction factor and heat
  • In vitro adventitious agent testing
08:50 - 09:00 10 mins
Cell Line Development & Engineering
Chairpersons Opening Remarks
09:00 - 09:30 30 mins
Cell Culture and Upstream Process Development
Operating in a Changing Landscape: Future Process Development Strategies
  • A Representative from Pall Life Sciences, Pall Life Sciences, USA
09:00 - 09:30 30 mins
Downstream Processing
Operating in a Changing Landscape: Future Process Development Strategies
  • A Representative from Pall Life Sciences, Pall Life Sciences, USA
09:00 - 09:30 30 mins
Process Development and Characterisation Strategies
Operating in a Changing Landscape: Future Process Development Strategies
  • A Representative from Pall Life Sciences, Pall Life Sciences, USA
09:00 - 09:30 30 mins
Bioprocess Analytics and Control Strategies
Operating in a Changing Landscape: Future Process Development Strategies
  • A Representative from Pall Life Sciences, Pall Life Sciences, USA
09:00 - 09:30 30 mins
Vaccines
Operating in a Changing Landscape: Future Process Development Strategies
  • A Representative from Pall Life Sciences, Pall Life Sciences, USA
09:00 - 09:30 30 mins
Cell Line Development & Engineering
Adapting Cell Line and Clone Selection Methods and Workflows for Continuous Manufacturing
  • Christine DeMaria - Director, Cell Line Development, Sanofi
09:30 - 10:00 30 mins
Cell Culture and Upstream Process Development
Future Strategies for Bioprocessing
  • Christian Eckermann - Head of Biopharma Austria & Member of the Biopharma Executive Committee, Boehringer Ingelheim RCV GmbH & CoKG
09:30 - 10:00 30 mins
Downstream Processing
Future Strategies for Bioprocessing
  • Christian Eckermann - Head of Biopharma Austria & Member of the Biopharma Executive Committee, Boehringer Ingelheim RCV GmbH & CoKG
09:30 - 10:00 30 mins
Process Development and Characterisation Strategies
Future Strategies for Bioprocessing
  • Christian Eckermann - Head of Biopharma Austria & Member of the Biopharma Executive Committee, Boehringer Ingelheim RCV GmbH & CoKG
09:30 - 10:00 30 mins
Bioprocess Analytics and Control Strategies
Future Strategies for Bioprocessing
  • Christian Eckermann - Head of Biopharma Austria & Member of the Biopharma Executive Committee, Boehringer Ingelheim RCV GmbH & CoKG
09:30 - 10:00 30 mins
Vaccines
Future Strategies for Bioprocessing
  • Christian Eckermann - Head of Biopharma Austria & Member of the Biopharma Executive Committee, Boehringer Ingelheim RCV GmbH & CoKG
09:30 - 10:00 30 mins
Cell Line Development & Engineering
Accelerating timelines close to the biological limit: A story about the value of implementing novel technologies
  • Thomas Jostock, PhD - Science and Technology Lead / Novartis Leading Scientist, Novartis Pharma AG
10:00 - 10:30 30 mins
Cell Culture and Upstream Process Development
Next Generation Bioprocessing Strategies
  • A Representative from GE Healthcare, GE Healthcare
10:00 - 10:30 30 mins
Downstream Processing
Next Generation Bioprocessing Strategies
  • A Representative from GE Healthcare, GE Healthcare
10:00 - 10:30 30 mins
Process Development and Characterisation Strategies
Next Generation Bioprocessing Strategies
  • A Representative from GE Healthcare, GE Healthcare
10:00 - 10:30 30 mins
Bioprocess Analytics and Control Strategies
Next Generation Bioprocessing Strategies
  • A Representative from GE Healthcare, GE Healthcare
10:00 - 10:30 30 mins
Vaccines
Next Generation Bioprocessing Strategies
  • A Representative from GE Healthcare, GE Healthcare
10:00 - 10:30 30 mins
Viral Safety
Spotlight Presentation
  • A Representative from Merck, Merck, UK
10:00 - 10:30 30 mins
Cell Line Development & Engineering
Spotlight Presentation
  • A Representative from Lonza, Lonza, Switzerland
10:30 - 11:30 60 mins
Morning Coffee and Networking
11:30 - 12:00 30 mins
Info
Cell Culture and Upstream Process Development
Intensified fed-batch platform to increase productivity
  • Stefania Caso - Technology and Innovation Post-Doctoral Scientist, Merck Serono SA

There is an emerging trend of implementing process intensification in upstream bioprocesses to maximize the cell culture productivity. This presentation provides insight into the development of an intensified fed-batch platform process. It offers a greater process efficiency with a smaller footprint. Examples include production of various monoclonal antibodies and a fusion antibody thanks to the use of this platform. In these cases we increased 2-4 times the titer with a product quality comparable to a classical fed-batch process and in shorter time.

11:30 - 12:00 30 mins
Process Development and Characterisation Strategies
Integrating QbD Principles and Process Characterization Approaches in Developing a Control Strategy for a Non-mAb Biologic
  • Kumar Dhanasekharan - Senior Director & Head Biologics, Amicus Therapeutics
11:30 - 12:00 30 mins
Info
Bioprocess Analytics and Control Strategies
Process Analytics Update: Data Integration And Predictive Analytics
  • Julian Morris - Technical Director , Centre for Process Analytics & Control Technology

The presentation will provide an update on (i) real time process analytics and process performance monitoring, (ii) the challenges of PAT callibration maintenance and transfer, (iii) progress towards lean six sigma operations, (iii) Data Integration, (iv) Factorie 4.0 and the potential for virtual (software) sensors and predictive analytics.

11:30 - 12:00 30 mins
Info
Vaccines
Neoantigen-based personalized cancer vaccines: the promise is enormous but so is the cost that at current levels could bankrupt even developed nations’ economies
  • Dan Adams - Executive Chairman and Global Head of Business Development, Protein Sciences Corporation, USA

This session will be address recent results and efforts to make these vaccines affordable.

11:30 - 12:00 30 mins
Info
Viral Safety
Continuous virus inactivation process using a novel packed-bed reacto
  • Duarte Martins - PhD Student, Lab of Protein Technology and Downstream Processing, Dept of Biotechnology, University of Natural Resources and Life Sciences
  • Marcel Asper - Director Virus Laboratory, Pathogen Safety, Biotest AG

Talk 1:  Continuous virus inactivation process using a novel packed-bed reactor

Duarte Martins, PhD Student, Lab of Protein Technology and Downstream Processing, Dept of Biotechnology, University of Natural Resources and Life Sciences, Vienna

 

Talk Two: Virus inactivation by laboratory and by manufacturing scale UV-C irradiation in products of Human Plasma

 UV-C irradiation is widely used for virus and pathogen inactivation of air, surfaces and liquids of low optical density (OD), e.g. WFI water. UV-C irradiation of protein solutions is less common due to the very restricted penetration depth of UV-C irradiation which poses severe technical challenges (mostly: homogeneity of irradiation).

An advanced UV-C irradiation technology (UVivatec (R)) is presented, which is used for plasma products in/close to clinical trials. Data are shown and discussed for virus inactivation by laboratory and by manufacturing scale UV-C irradiation.

Marcel Asper, Director Virus Laboratory, Pathogen Safety, Biotest AG, Germany 

11:30 - 12:00 30 mins
Cell Line Development & Engineering
Case Study from Amgen: Accelerating Cell Line Development
  • Christopher Tan - Scientist, Amgen
12:00 - 12:30 30 mins
Info
Cell Culture and Upstream Process Development
Pitfalls And Learnings - Transition From Early To Late Stage Process Development Activities
  • Sebastian Schwamb - Laboratory Head, Cell Culture Development in R&D Biologics Development, Sanofi

The presentation will get into current Sanofi state of the art upstream process development centered on late stage programs.

Hereby the theoretical approach, of how to accomplish a successful transition from early to late stage development will be presented.

Furthermore distinct examples of individual development packages (e. g. scale-down) for a Sanofi-proprietary IgG-like molecule will be shown.

12:00 - 12:30 30 mins
Downstream Processing
Innovative Manufacturing Strategies - What are the Economic Drivers?
  • Andrew Sinclair - President and Founder, BioPharm Services Ltd, United Kingdom
12:00 - 12:30 30 mins
Process Development and Characterisation Strategies
Strategies in Setting Up Phase-Appropriate CQAs for Non-mAb Biologics
  • Zhimei Du, PhD - Director, Merck & Co
12:00 - 12:30 30 mins
Bioprocess Analytics and Control Strategies
Case Study from Shire: Global Implementation of Real Time Monitoring
  • Michael Backhaus - Manager Manufacturing Intelligence IT Lead, Shire
12:00 - 12:30 30 mins
Vaccines
Challenges in Multicomponent Vaccine Development and Manufacturing
  • A. Krishna Prasad, Ph.D. - Director, Vaccine Research, Pfizer Inc.
12:00 - 12:30 30 mins
Viral Safety
Virus inactivation by laboratory and by manufacturing scale UV-C irradiation in products of Human Plasma
  • Marcel Asper - Director Virus Laboratory, Pathogen Safety, Biotest AG
12:00 - 12:30 30 mins
Cell Line Development & Engineering
The BEST of Both Worlds – Targeted Integration and Multiple Copies: How Can This Go Together For Improved Cell Line Development?
  • Anton Bauer - Senior Scientist, Medical University of Vienna
12:30 - 13:00 30 mins
Cell Culture and Upstream Process Development
Spotlight Presentation
  • A Representative from GE Healthcare, GE Healthcare
12:30 - 13:00 30 mins
Downstream Processing
Spotlight Presentation
  • A Representative from Thermo Fisher Scientific, Thermo Fisher Scientific, USA
12:30 - 13:00 30 mins
Process Development and Characterisation Strategies
Spotlight Presentation
  • A Representative from Sartorius, Sartorius
12:30 - 13:00 30 mins
Bioprocess Analytics and Control Strategies
Spotlight Presentation
12:30 - 13:00 30 mins
Vaccines
Purity analysis of gene therapy vectors from process development to commercial process
  • Josefina Nilsson - Head of EM Services, Vironova
12:30 - 13:00 30 mins
Viral Safety
Spotlight Presentation
  • A Representative from Pall Life Sciences, Pall Life Sciences, USA
12:30 - 12:45 15 mins
Cell Line Development & Engineering
Spotlight Presentation
  • A Representative from Valitacell, Valitacell
12:45 - 13:00 15 mins
Cell Line Development & Engineering
Spotlight Presentation
  • A Representative from Batavia Biosciences, Batavia Biosciences
13:00 - 13:30 30 mins
Lunch in the Exhibition Hall
13:30 - 14:15 45 mins
Live Labs
14:15 - 14:45 30 mins
Info
Cell Culture and Upstream Process Development
From Bench To Production: Addressing The Challenges Of Process Development For Novel Highly Potent Therapeutics
  • Alison Mason - Head of Upstream Development, Ipsen Biopharm

Botulinum neurotoxin (BoNT), produced by Clostridium botulinum, is an effective treatment for several movement disorders. An increased understanding of the structure-function relationship of BoNT molecules provides opportunities to engineer recombinant (r) BoNTs with unique pharmacologic properties and therapeutic applications. This presentation describes the challenges and opportunities associated with process development and GMP manufacture for rBoNT products.

14:15 - 14:45 30 mins
Downstream Processing
Development of Continuous Capture Process of Antibodies Using Different Protein A Resins: Loading Strategy, Process Design and Other Considerations
  • Xuezhen Connie Kang, Ph.D - Principal Scientist, Continuous Manufacturing Skill Center, Sanofi
14:15 - 14:45 30 mins
Process Development and Characterisation Strategies
Process Characterization Over Multiple Unit Operations
  • Elisabeth Meulenbroek - Scientist DSP, Janssen Vaccines
14:15 - 14:45 30 mins
Info
Bioprocess Analytics and Control Strategies
Manufacturing Continuous Process Improvement for Enhancing the Product Quality Control Capability by Process Validation Lifecycle and Implementing PAT Platform
  • Ting-Kuo Huang, PhD - Senior Engineer, Genentech, Inc

During biopharmaceutical process development and commercialization, the Process Validation lifecycle is started with Process Design (Stage 1), then followed by Process Performance Qualification (Stage 2) and monitored through Continued Process Verification (Stage 3) for a marketed biologics product. The CPV (Continued Process Verification), per Stage 3 of FDA Process Validation guidance, provides further assurance that a validated process remains in a state of control during the routine GMP manufacturing of a marketed biologics product lifecycle. Raw material lot-to-lot variability may potentially lead to unexpected impact on the cell culture manufacturing process performance and/or product quality attributes (e.g., slower cell growth, low titer performance and/or drifting or shifting of product quality attributes, etc.). Therefore, the manufacturing process performance and product quality attributes (PQA) are continuously monitored, verified and controlled throughout the marketed biologics product lifecycle.

In this presentation, an industry case study will discuss – how a cell culture manufacturing process improvement was identified, evaluated and implemented for stabilizing and controlling the drug substance PQAs to mitigate the potential impact of raw material variability for a marketed biologics product. Multivariate data analysis, scale-down model approaches, and commercial scale process validation were developed, employed and executed to improve the control capability of PQAs. Furthermore, the associated process improvement, CAPA, manufacturing control strategies, and implementing PAT platform in GMP for enhancing product and process monitoring and control during lifecycle will also be presented. The outcome and progress presented in this study are intended to enhance biopharmaceutical manufacturing process knowledge, which is valuable for all partners across the cell culture manufacturing network.

14:15 - 14:45 30 mins
Info
Vaccines
A presentation from Bio-Rad
14:15 - 14:45 30 mins
Viral Safety
Environmental restrictions and use of alternatives to Triton X-100 in virus inactivation
  • Johanna Kindermann - Manager, Pathogen Safety, Shire
  • Jean-Baptiste Farcet - Senior Development Scientist, Process Development, Shire
14:15 - 14:45 30 mins
Cell Line Development & Engineering
End-to-end Workflow Platform to Speed Up Cell Line Development at Highest Quality Standards
  • Christoph Freiberg - Senior Scientific Consultant, Biologics, Genedata
14:45 - 15:15 30 mins
Cell Culture and Upstream Process Development
Case Study: Lessons Learnt from Scale Up of Upstream Processes
  • Matthew Osbourne - Director, Biotech Technical Services/ Manufacturing Sciences, Eli Lilly Kinsale Limited
14:45 - 15:15 30 mins
Downstream Processing
Achieving Cost and Process Time Savings with Continuous Chromatography and Process Integration for Biotherapeutics
  • Thomas Mueller-Spaeth, Ph.D - Senior Scientist, Institute for Chemical and Bioengineering, ETH Zurich
14:45 - 15:15 30 mins
Process Development and Characterisation Strategies
talk to follow
14:45 - 15:15 30 mins
Info
Bioprocess Analytics and Control Strategies
Modern Analytical Approaches in supporting Process Development
  • Martin Mueller - Director BioProcess Development, MSD

After years of hitting on the product and lifting up even complex biologics to the ‘well-characterized’ category, significant progress has been made with innovative analytical technology focussing on earlier process steps. The benefits and limits of such new control strategies are discussed by case studies applying techniques like PAT, MAM, residual analytics and real-time release approaches.

14:45 - 15:15 30 mins
Vaccines
Improving downstream processing of vaccines and gene therapy vectors with continuous chromatography
  • Manuel Carrondo - Professor of Chemical and Biochemical Engineering, FCT-UNL Vice-President, iBET Portugal
14:45 - 15:15 30 mins
Info
Viral Safety
Effective inactivation of a wide range of viruses by pasteurisation
  • Wolfram Schäfer - Senior Manager, Virus Safety Development, CSL Behring Biotherapies for Life

Pasteurization at 60°C for 10 hours has been implemented in the manufacturing process of therapeutic plasma proteins such as human albumin, coagulation factors, immunoglobulins, and enzyme inhibitors to inactivate blood-borne viruses of concern. A comprehensive compilation of the virus reduction capacity of pasteurization will be presented including the effect of stabilizers used to protect the therapeutic protein from modifications during heat treatment. Virus spiking studies were carried out under the routine manufacturing target variables, such as temperature and product-specific stabilizer composition. Additional studies were also performed under robustness conditions i.e. outside production specifications. Evidence will be provided that pasteurization is a very robust and reliable virus inactivation method with a broad effectiveness against enveloped and non-enveloped viruses encompassing known blood-borne pathogens and emerging or potentially emerging viruses.

14:45 - 15:15 30 mins
Cell Line Development & Engineering
Rapid Development of Cell Lines Suitable for Commercial Manufacturing
  • Martin J. Allen, Ph.D. - Senior Director, BioProcess Research & Development, Pfizer
15:15 - 15:45 30 mins
Cell Culture and Upstream Process Development
Spotlight Presentation
  • A Representative from Merck, Merck, UK
15:15 - 15:45 30 mins
Downstream Processing
Spotlight Presentation from Chiral Technologies
15:15 - 15:45 30 mins
Process Development and Characterisation Strategies
Spotlight Presentation
  • A Representative from Thermo Fisher Scientific, Thermo Fisher Scientific, USA
15:15 - 15:45 30 mins
Bioprocess Analytics and Control Strategies
Spotlight Presentation
15:15 - 15:45 30 mins
Vaccines
Spotlight Presentation
  • A Representative from GE Healthcare, GE Healthcare
15:15 - 15:45 30 mins
Viral Safety
Spotlight Presentation
  • A Representative from Sartorius, Sartorius
15:15 - 15:45 30 mins
Info
Cell Line Development & Engineering
Scalable, Helper Virus-Free AAV Production in Suspension
  • Silke Wissing - Vice President R&D, CEVEC

CEVEC has developed a helper virus-free suspension AAV production platform on the basis of the CAP-GT cells. These human suspension cell lines grow to high density in serum free conditions and allow reproducible and high titer production of viral vectors. CEVEC’s stable AAV packaging/producer cell lines enables a consistent quality production of AAV vectors that abolishes the need for transient transfection or helper-virus transduction.

15:45 - 16:15 30 mins
Afternoon Coffee & Networking
16:15 - 16:45 30 mins
Info
Cell Culture and Upstream Process Development
Monitoring The Scale-Up Of A Biopharmaceutical Cell Culture Process Using Raman Spectroscopy At 2000 L Scale In A GMP Environment
  • Rutger Douma - Senior Scientist/Manager Technical Operations, Janssen Biologics

A Raman spectroscopic model was developed using small scale cell culture bioreactor experiments for a new Janssen biopharmaceutical product. This model enabled online substrate, metabolite and product concentration measurements and it was successfully used to monitor the scale-up to a 2000 L fed-batch bioreactor in a GMP environment.

16:15 - 16:45 30 mins
Downstream Processing
Intensified Processing - Can I Meet my Viral Safety Targets?
  • Sladjana Tomić-Škrbić - Manager, Merck
16:15 - 16:45 30 mins
Bioprocess Analytics and Control Strategies
Monitoring The Scale-Up Of A Biopharmaceutical Cell Culture Process Using Raman Spectroscopy At 2000 L Scale In A GMP Environment
  • Rutger Douma - Senior Scientist/Manager Technical Operations, Janssen Biologics
16:15 - 16:45 30 mins
Vaccines
Efforts on the development and licensure of an Ebola vaccine
  • Parimal Desai - Vice President, Global Vaccines & Biologics Commercialization, Merck
16:15 - 16:45 30 mins
Viral Safety
Roche Diagnostics GmbH Case Stud
  • Marc Bieberbach - Senior Research Associate, Roche Diagnostics GmbH
16:15 - 16:45 30 mins
Info
Cell Line Development & Engineering
Making the Most Out of the Data Collected along the CLD Process
  • Anke Mayer-Bartschmid, - Cell and Protein Sciences, Pharmaceuticals Division, , Bayer Pharma

High titers and good product quality are the key features a final production cell line needs to have. Besides many other quality attributes a consistent track record and data integrity are essential to launch the cell line for production. Furthermore, the availability of screening data during cell line development allows for fast analysis and the selection of the best clones. We will present Bayer’s way for tracking and analysis of clone selection data.

16:45 - 17:15 30 mins
Cell Culture and Upstream Process Development
Advances in Real-Time Online Monitoring Methods for Product Quality in Cell Culture Bioreactors
  • Keith Wilson - Head of Bioprocess R&D, Novimmune
16:45 - 17:15 30 mins
Downstream Processing
Achieving Fully Integrated Downstream Continuous Process - What Challenges Still Remain?
  • Gorazd Hribar - Project Manager, nextBioPharmDSP, Novartis
16:45 - 17:15 30 mins
Bioprocess Analytics and Control Strategies
Advances in Real-Time Online Monitoring Methods for Product Quality in Cell Culture Bioreactors
  • Keith Wilson - Head of Bioprocess R&D, Novimmune
16:45 - 17:15 30 mins
Viral Safety
Please move to another track
16:45 - 17:15 30 mins
Info
Cell Line Development & Engineering
KEYNOTE: Engineering Complex Traits in CHO Cells through Multiplex Genome Editing
  • Nathan Lewis - Assistant Professor, University of California, San Diego

CHO remains the primary host cell for producing most biotherapeutics. However, there remain many traits that could be improved in the cells. Here, I will discuss recent work in our lab were we utilized systems biology approaches to identify genes to target for host cell engineering to improve cell line and bioprocess quality.

17:15 - 17:20 5 mins
Plenary Changeover
17:20 - 17:50 30 mins
Cell Culture and Upstream Process Development
Next Generation Bioprocessing Strategies
  • A Representative from Sartorius, Sartorius
17:20 - 17:50 30 mins
Downstream Processing
Next Generation Bioprocessing Strategies
  • A Representative from Sartorius, Sartorius
17:20 - 17:50 30 mins
Process Development and Characterisation Strategies
Next Generation Bioprocessing Strategies
  • A Representative from Sartorius, Sartorius
17:20 - 17:50 30 mins
Bioprocess Analytics and Control Strategies
Next Generation Bioprocessing Strategies
  • A Representative from Sartorius, Sartorius
17:20 - 17:50 30 mins
Vaccines
Next Generation Bioprocessing Strategies
  • A Representative from Sartorius, Sartorius
17:20 - 17:50 30 mins
Viral Safety
Next Generation Bioprocessing Strategies
  • A Representative from Sartorius, Sartorius
17:20 - 17:50 30 mins
Cell Line Development & Engineering
Next Generation Bioprocessing Strategies
  • A Representative from Sartorius, Sartorius
17:50 - 18:20 30 mins
Info
Cell Culture and Upstream Process Development
Industry 4.0 in Aviation – Digitalization without beta versions
  • Sven Taubert - Head of Corporate Foresight & Market Intelligence, Lufthansa Technik AG

Topics like Digitalization and Industry 4.0 are currently on everyone's minds. New economy companies revolutionizing more and more classical business models. Aviation, like other safety sensitive industries, is working hard to keep up. Unlike services from the big role models out of e.g. Silicon Valley, aerospace products cannot and will not shipped in Beta status. This presentation will show examples how Lufthansa is addressing these challenges.

17:50 - 18:20 30 mins
Info
Downstream Processing
Industry 4.0 in Aviation – Digitalization without beta versions
  • Sven Taubert - Head of Corporate Foresight & Market Intelligence, Lufthansa Technik AG

Topics like Digitalization and Industry 4.0 are currently on everyone's minds. New economy companies revolutionizing more and more classical business models. Aviation, like other safety sensitive industries, is working hard to keep up. Unlike services from the big role models out of e.g. Silicon Valley, aerospace products cannot and will not shipped in Beta status. This presentation will show examples how Lufthansa is addressing these challenges.

17:50 - 18:20 30 mins
Info
Process Development and Characterisation Strategies
Industry 4.0 in Aviation – Digitalization without beta versions
  • Sven Taubert - Head of Corporate Foresight & Market Intelligence, Lufthansa Technik AG

Topics like Digitalization and Industry 4.0 are currently on everyone's minds. New economy companies revolutionizing more and more classical business models. Aviation, like other safety sensitive industries, is working hard to keep up. Unlike services from the big role models out of e.g. Silicon Valley, aerospace products cannot and will not shipped in Beta status. This presentation will show examples how Lufthansa is addressing these challenges.

17:50 - 18:20 30 mins
Info
Bioprocess Analytics and Control Strategies
Industry 4.0 in Aviation – Digitalization without beta versions
  • Sven Taubert - Head of Corporate Foresight & Market Intelligence, Lufthansa Technik AG

Topics like Digitalization and Industry 4.0 are currently on everyone's minds. New economy companies revolutionizing more and more classical business models. Aviation, like other safety sensitive industries, is working hard to keep up. Unlike services from the big role models out of e.g. Silicon Valley, aerospace products cannot and will not shipped in Beta status. This presentation will show examples how Lufthansa is addressing these challenges.

17:50 - 18:20 30 mins
Info
Vaccines
Industry 4.0 in Aviation – Digitalization without beta versions
  • Sven Taubert - Head of Corporate Foresight & Market Intelligence, Lufthansa Technik AG

Topics like Digitalization and Industry 4.0 are currently on everyone's minds. New economy companies revolutionizing more and more classical business models. Aviation, like other safety sensitive industries, is working hard to keep up. Unlike services from the big role models out of e.g. Silicon Valley, aerospace products cannot and will not shipped in Beta status. This presentation will show examples how Lufthansa is addressing these challenges.

17:50 - 18:20 30 mins
Info
Viral Safety
Industry 4.0 in Aviation – Digitalization without beta versions
  • Sven Taubert - Head of Corporate Foresight & Market Intelligence, Lufthansa Technik AG

Topics like Digitalization and Industry 4.0 are currently on everyone's minds. New economy companies revolutionizing more and more classical business models. Aviation, like other safety sensitive industries, is working hard to keep up. Unlike services from the big role models out of e.g. Silicon Valley, aerospace products cannot and will not shipped in Beta status. This presentation will show examples how Lufthansa is addressing these challenges.

17:50 - 18:20 30 mins
Info
Cell Line Development & Engineering
Industry 4.0 in Aviation – Digitalization without beta versions
  • Sven Taubert - Head of Corporate Foresight & Market Intelligence, Lufthansa Technik AG

Topics like Digitalization and Industry 4.0 are currently on everyone's minds. New economy companies revolutionizing more and more classical business models. Aviation, like other safety sensitive industries, is working hard to keep up. Unlike services from the big role models out of e.g. Silicon Valley, aerospace products cannot and will not shipped in Beta status. This presentation will show examples how Lufthansa is addressing these challenges.

18:20 - 19:50 90 mins
End of Conference Day Two and Evening Party